Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

Thomas Powles; Michael Staehler; Börje Ljungberg; Karim Bensalah; Steven E Canfield; Saeed Dabestani; Rachel Giles; Fabian Hofmann; Milan Hora; Markus a Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Alessandro Volpe; Axel Bex

doi:10.1016/j.eururo.2015.10.017

Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

Thomas Powles, Michael Staehler, Börje Ljungberg, Karim Bensalah, Steven E Canfield, Saeed Dabestani, Rachel Giles, Fabian Hofmann, Milan Hora, Markus a Kuczyk, Thomas Lam, Lorenzo Marconi, Axel S Merseburger, Alessandro Volpe, Axel Bex

Klinik für Urologie

98 Zitate (Scopus)

Abstract

The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.

Originalsprache	Englisch
Zeitschrift	European Urology
Seiten (von - bis)	9-11
Seitenumfang	3
ISSN	0302-2838
DOIs	https://doi.org/10.1016/j.eururo.2015.10.017
Publikationsstatus	Veröffentlicht - 24.10.2015

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Dokumente

10.1016/j.eururo.2015.10.017

Zitieren

@article{00d90e5674a845b693ce5a5ee01ae111,

title = "Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.",

abstract = "The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.",

author = "Thomas Powles and Michael Staehler and B{\"o}rje Ljungberg and Karim Bensalah and Canfield, \{Steven E\} and Saeed Dabestani and Rachel Giles and Fabian Hofmann and Milan Hora and Kuczyk, \{Markus a\} and Thomas Lam and Lorenzo Marconi and Merseburger, \{Axel S\} and Alessandro Volpe and Axel Bex",

year = "2015",

month = oct,

day = "24",

doi = "10.1016/j.eururo.2015.10.017",

language = "English",

pages = "9--11",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

AU - Powles, Thomas

AU - Staehler, Michael

AU - Ljungberg, Börje

AU - Bensalah, Karim

AU - Canfield, Steven E

AU - Dabestani, Saeed

AU - Giles, Rachel

AU - Hofmann, Fabian

AU - Hora, Milan

AU - Kuczyk, Markus a

AU - Lam, Thomas

AU - Marconi, Lorenzo

AU - Merseburger, Axel S

AU - Volpe, Alessandro

AU - Bex, Axel

PY - 2015/10/24

Y1 - 2015/10/24

N2 - The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.

AB - The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.

U2 - 10.1016/j.eururo.2015.10.017

DO - 10.1016/j.eururo.2015.10.017

M3 - Journal articles

C2 - 26508312

SN - 0302-2838

SP - 9

EP - 11

JO - European Urology

JF - European Urology

ER -

Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

Abstract

UN SDGs

Dokumente

Fingerprint

Zitieren